Letter from the Editor

Dear colleagues,

Thank you for your interest in this edition of Medicom’s Conference Report covering the Heart Failure Association’s 2023 Annual Meeting.

This year’s meeting was filled with late breaking clinical trials, innovative science, and new developments in structural cardiology.

In the following pages you will read about new data regarding the role of hemodynamic monitoring in reducing hospitalizations in patients with heart failure, the spectrum of biomarker and imaging benefits associated with SGLT2 inhibitors, novel approaches to improving adoption of influenza vaccinations, as well as novel therapies for HOCM and amyloid.  As always, our summaries are written independently and are peer-reviewed for balance. We hope you find this edition informative, engaging, and balanced and thank you again for your readership.

Sincerely,

Marc Bonaca

Biography

Marc P. Bonaca, MD, MPH, is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado Anschutz Medical Campus. He is the Director of Vascular Research and Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research.

Dr Bonaca earned his medical degree from the University of Connecticut School of Medicine and his Masters in Public Health at Harvard University. He served as a Medical House Officer at Brigham and Women’s Hospital and Harvard Medical School. After completion of his training, he joined the faculty of the Cardiovascular Division and Vascular Medicine section of Brigham and Women’s Hospital and Harvard Medical School and became an Investigator at the TIMI Study Group.

Dr Bonaca’s research focus is on ischemic risk in patients with atherosclerotic vascular disease, risk prediction, and risk modification through the use of pharmacologic and biologic therapies. His key areas of interest include patients with peripheral artery disease, polyvascular disease and diabetes with a focus on the breadth of risk including ischemic limb outcomes, microvascular complications and major adverse cardiovascular events.

Conflict of Interest Statement:

Grant support to BWH from AstraZeneca, MedImmune, Merck, PfizerGrant support to CPC from Amgen, AstraZeneca, Bayer, Janssen, NovoNordisk, Sanofi.



Posted on 8 August 20238 August 2023